Scotland recorded its lowest number of births for a third consecutive year in 2025, with 45,067 live births registered.

The total was almost 696 fewer than the previous year and the lowest annual figure since records began in 1855.

Deaths also outnumbered births for the 11th consecutive year, with the gap between the two generally widening since 2014.

Registrar General and National Records of Scotland chief executive Alison Byrne said: “This is the eleventh year in a row where deaths have outnumbered births and the third in a row where we have a new record low for the number of births in Scotland.

“Generations of change are captured in these figures.

“This data will inform debate and decision-making across the public and private sectors, as we consider what this means for our future.”

Figures published by the National Records of Scotland (NRS) show the country’s total fertility rate fell to 1.23 in 2025, from 1.24 in 2024.

The total fertility rate measures the average number of children born to each woman. A rate of around 2.1 is needed for a population to replace itself without migration.

Scotland’s 2025 figure was the lowest since the start of the NRS-published time series in 1951. The country’s fertility rate was last above 2.1 in 1973.

Despite the decline in births, Scotland’s population increased slightly in the year to June 2025, driven by migration.

The annual figures also showed an increase in stillbirths, from 159 in 2024 to 188 in 2025.

This represented 4.2 stillbirths for every 1,000 live and stillbirths, compared with 3.5 in 2024. The 2024 figure was the joint lowest stillbirth rate recorded for any year and remains historically low.

The infant death rate fell from 3.5 per 1,000 live births in 2024 to 3.3 in 2025.

Adoptions declined from 369 in 2024 to 340 in 2025.

Meanwhile, 27,191 marriages took place in Scotland during 2025, 236 more than the previous year. Four per cent were same-sex marriages and 96 per cent were mixed-sex marriages.

Civil partnerships increased to 944, the highest number since 2006, the first full year in which civil partnerships were available.

The figures form part of the NRS annual release covering births, marriages, deaths and other vital life events in Scotland.

Applications close 2 September at 12pm BST for W Accelerate with Merck KGaA and M Ventures, a fast-track programme offering startups, scaleups and spinouts in reproductive and maternal health direct access to decision-makers at one of the world’s leading reproductive health companies.

With a single application, innovators connect with Merck KGaA’s partnership team and investment professionals from M Ventures, Merck’s corporate venture arm.

Selected companies will be notified on 11 September and invited to pitch at W Accelerate in London, at One Hundred Shoreditch, on 5 October.

During the event, they will receive a private 30-minute session with Merck and M Ventures leadership, small-group guidance from regulation and investment specialists, an “Ask Merck Anything” roundtable, and access to a VIP networking reception.

Applications are open to companies working on breakthrough solutions across reproductive and maternal health, including fertility, endometriosis, adenomyosis, ovarian health, preeclampsia and pregnancy comorbidities.

Applicants can choose one of three lanes,  depending on whether they’re seeking strategic collaboration, investment, or both: Partnership Lane, Investment Lane, or Dual Lane. Direct-to-consumer and over-the-counter products are outside the programme’s scope.

Thang Vo-Ta, CEO & co-founder of Calla Lily Clinical Care and participant of a previous edition of W Accelerate with Merck Healthcare and M Ventures, said: “The opportunity to pitch directly to senior leadership at Merck and M Ventures sparked conversations that became the foundation of relationships leading to our eventual strategic collaboration with Merck. I’ve yet to see another event run with this level of excellence.”

For more information, visit W Group’s website: wplatform.co

Applications close 2nd September 2026, 12pm BST

W Accelerate event: 5th October 2026 at One Hundred Shoreditch, London (travel and accommodation not provided)

Apply here

Chelsea FC Women is to launch a fertility fund giving players access to assessments, treatments, counselling and workshops.

The initiative is part of a new partnership with London fertility clinic Fertility Plus, which has been named the club’s official fertility partner.

Chelsea said the fund will be available to every player in its women’s team, with support tailored to individual needs.

Giulia Mazzia, commercial director for Chelsea FC Women, said: “At Chelsea FC Women we are never done pushing for progress for our players and our community.

“This first-of-its-kind partnership with Fertility Plus will open up the conversation about fertility, help to raise awareness for our incredible fanbase and beyond, and give practical support to our players off the field as well as on it.”

Support through Fertility Plus will include fertility assessments and treatments, as well as counselling and workshops.

The partnership will also provide evidence-based information about reproductive health and address misconceptions around fertility.

Chelsea cited previous research on fertility knowledge which found that 41 per cent of respondents actively trying to conceive did not know when their fertile window was.

The club and Fertility Plus plan to provide educational content, resources comparing fertility myths with medical evidence and insights from Chelsea FC Women ambassadors.

Dr Amit Shah and Dr Anil Gudi, co-founders of Fertility Plus, said: “Elite sport asks a lot of women during the very years when fertility matters most, yet it’s a conversation the game has rarely had.

“Partnering with Chelsea FC Women allows us to help change that by giving players, staff and supporters access to trusted fertility expertise and compassionate, consultant-led care.

“We’re proud to work alongside a club that’s setting a new standard for supporting women’s health, both on and off the pitch.